U095 Prurigo Nodularis
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session will provide a cutting-edge discussion about our current understanding of prurigo nodularis (PN), with novel insights into disease burden, pathophysiology, and emerging therapeutics, and vulnerable patient populations. This session is directed towards dermatologists and other health care providers who treat adults with prurigo nodularis.
LEARNING OBJECTIVES
Recognize the high burden of disease and comorbidities of prurigo nodularis
Identify the clinical characteristics and pathophysiology of prurigo nodularis
Describe therapeutic decision making for prurigo nodularis
SCHEDULE
11:30 PM
Updates in Prurigo Nodularis Clinical Approach & Pathophysiology
Shawn Kwatra, MD, FAAD
12:00 AM
Therapeutic Approach for Prurigo Nodularis
Shawn Kwatra, MD, FAAD, Sarina Elmariah, MD, FAAD
SPEAKERS
Sarina Elmariah, MD, FAAD
Shawn Kwatra, MD, FAAD
SPEAKER DISCLOSURES
Sarina Elmariah, MD, FAAD
Eli Lilly – Other(Honoraria); Galderma Laboratories, LP – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria);
Shawn Kwatra, MD, FAAD
AbbVie – Consultant(Honoraria); Amgen – Advisory Board(Honoraria); Arcutis Biotherapeutics – Advisory Board(Honoraria); ASLAN Pharmaceuticals – Consultant(Honoraria); Cara Therapeutics – Advisory Board(Honoraria); Castle Biosciences, Inc – Consultant(Honoraria); Celldex – Consultant(Honoraria); Galderma – Investigator(Grants/Research Funding); Galderma USA – Consultant(Honoraria); Incyte Corporation – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Johnson and Johnson – Advisory Board(Honoraria); Leo Pharma Inc – Advisory Board(Honoraria); Novartis – Consultant(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Regeneron – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria), Investigator(Grants/Research Funding);